English
/
Français
Ethics Portal
Who We Are
Who We Are
About Us
Business Model
Our Strategy 2023-2025
Statutes, By-Laws & Policies
Governance & Team
Annual Reports
Careers & RFPs
What We Do
What We Do
Licensing for Public Health
mRNA Technology Transfer Hub Programme
Disease Areas
Addressing Children’s Needs
Prioritising Medicines for Licensing
Long-Acting Therapeutics
Focus areas
Biotherapeutics
Local and Regional Manufacturing
Pandemic Preparedness and Response
Upstream Access
Technology Transfer
Patent Information Tools
MedsPaL
LAPaL
Progress
Progress
Licences
Prioritisation
Agreements with Innovators
Access to Medicines Tracker
Contribution to Universal Health Coverage
Endorsements
Impact
News & Publications
News
& Publications
News, Events & Press Releases
Messages from the Executive Director
MPP in the Media
MPP Publications
Related Publications
Newsletters & Updates
Partners
Partners
Partnering with MPP
Funders
Our Stories
Voices from Friends of MPP
Voices from the Frontline
I am part of the DTG story
How to Give or Get a Licence
Contact Us
English
/
Français
Ethics Portal
Our
Projects
M
RNA Technology Transfer Programme
12 April 2022
VaxPaL
08 June 2021
News & Press Releases » News
MPP welcomes WHO announcement of the first COVID-19 mRNA vaccine technology transfer hub to be established in South Africa
22 June 2021
News & Press Releases » Press Releases
The Medicines Patent Pool (MPP) and MSD enter into licence agreement for molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access in low- and middle- income countries
27 October 2021
News & Press Releases » Press Releases
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
16 November 2021
COVID-19 Open Pledge
12 November 2020
MPP and COVID-19
Overview
COVID-19
08 October 2021